Anti Depressant Market Report
Anti-Depressant Market Trends, Dynamics & Market Insights See less
Anti-Depressant Market Trends, Dynamics & Market Insights
Anti-Depressant Market, By Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist, Reuptake Inhibitors, Others), End-User (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others), and Region - COVID-19 Impact Analysis and Forecast to 2026.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Anti-Depressant market. The historic years considered for the study are 2016-2019, the base year is 2020, and the forecast period is 2021-2026.
Anti-Depressant Market, By Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist, Reuptake Inhibitors, Others), End-User (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others), and Region ...
The Anti-Depressant market is projected to grow from USD 14.3 billion in 2020 to USD 17.5 billion by 2026 at a CAGR of around 3.4% during the forecast period.
Antidepressants can be defined as drugs that help to alleviate depressive symptoms, anxiety disorders, social anxiety disorder, and dysthymia among others. The antidepressant drugs available in the market include tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonists, and reuptake inhibitors among others.
Key players operating in the Anti-Depressant market are-
The growth of the anti-depressant market is primarily driven by an increasing number of people suffering from depression. Expanding geriatric populace across geographies coupled with rising spending on healthcare is expected to propel the market growth at a significant rate during the review period. Additionally, a growing emphasis on initiatives aimed at creating awareness regarding the disease state is likely to create lucrative opportunities for the market players during the review period.
By depressive disorder, the anti-depressant market has been bifurcated into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others. Under these, the major depressive disorder segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment growth can be an increasing number of people suffering from depression.
By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The regional growth is primarily attributed to the high prevalence of depression, expanding geriatric populace, and presence of key market players such as Bristol Myers Squibb (US) and Eli Lilly and Company (US). The market growth in the Asia-Pacific region is expected to be driven by rising awareness among consumers regarding depression disease in developing countries, particularly China and India.
The outbreak of the COVID-19 virus has affected the growth of the healthcare industry significantly. Stringent lockdown measures and restricted movement of people affected the product supply for a short period and thus, affected the market growth.
Here is the list of the group of customers that the anti-depressants market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at email@example.com.
The anti-depressant market is expected to witness an impressive growth of 3.4% CAGR in the coming years.
Alkermes (Ireland), Allergan, Inc. (Ireland), Bristol Myers Squibb (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), H. Lundbeck A/S (Denmark), The Merck Group (Germany), Pfiz-er Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel) and The Takeda Pharmaceutical Company Limited (Japan) are among the key players in the anti-depressant market.
The anti-depressant market size is expected to reach USD 17.5 billion in the foreseeable future.
North America is expected to grow at a significant CAGR in the anti-depressant market in the next five years.
The major depressive disorder segment accounted for the largest share in the anti-depressant market in 2020.
Anti-depressant distributors, Anti-depressant suppliers, Anti-depressant manufacturers, Logistics organizations, Government bodies are the target audience in the anti-depressant market.